ACT-777991: Next-Generation CXCR3 Antagonist in Phase I Trials for Type 1 Diabetes

ACT-777991

oral reversible CXCR3 antagonist Ph. I in healthy subjects opt. of known CXCR3 antagonists J. Med. Chem., March 8, 2023 Idorsia Pharmaceuticals Ltd, CH

Drug Hunter Team

ACT-777991, oral reversible CXCR3 antagonist, Ph. I in healthy subjects, opt. of known CXCR3 antagonists, J. Med. Chem., March 8, 2023, IDORSIA PHARMACEUTICALS LTD, CH

ACT-777991: Next-Generation CXCR3 Antagonist in Phase I Trials for Type 1 Diabetes

ACT-777991

Other molecules you may be interested in